Document is current

Article History

Received: 13 October 2020

Accepted: 16 February 2021

First Online: 3 April 2021

Disclosure

: MR reports grants, personal fees, and nonfinancial support from Celgene (a Bristol-Myers Squibb Company), Baxalta, Shire, Eli Lilly and Company, Pfizer, Novocure, Novartis, AstraZeneca, Sanofi, Baxter, Servier, and Boston Pharmaceuticals; JB reports employment with Bristol-Myers Squibb Company; AH reports consulting work for Ipsen, Merck, AbbVie, Applied Advanced Therapeutics, and Novartis; CPL and ACD have nothing to disclose; TM reports honoraria for consultancy with Advance Medical HCMS, Baxter, BioLineRX Ltd, Celgene SLU, Eisai, Genzyme, Incyte, IPSEN Pharma Lab, Menarini Lab, Servier, Lilly, Merck Sharp and Dohme, Prime Oncology EU, QED Therapeutics Inc, Sanofi-Aventis and declares institutional financial interests (paid directly to his institution) with Agios, Aslan, AstraZeneca, Bayer, Celgene (a Bristol-Myers Squibb Company), Genentech, Hallozyme, Immunomedics, Lilly, Merrimack, Millennium, Novartis, Pfizer, Pharmacyclics, and Roche; DYO reports consulting/advisory role with AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho Pharmaceutical, and Aslan Pharmaceuticals; research funding from AstraZeneca, Novartis, Array BioPharma, Eli Lilly and Company, and GC Pharma; HR reports consulting/advisory role with Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene (a Bristol-Myers Squibb Company), Daiichi Sankyo, Johnson & Johnson, and Pfizer; speakers bureaus from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene (a Bristol-Myers Squibb Company), Daiichi Sankyo, LEO Pharma, and Pfizer; research funding from Bayer, Celgene (a Bristol-Myers Squibb Company), and LEO Pharma; MT reports consulting with AbbVie, Advance Medical, BioPharm Communications, Bristol-Myers Squibb Company, Celgene (a Bristol-Myers Squibb Company), Eisai, Ignyta, Pharmacyclics, PharmaCyte Biotech, and Tocagen; advisory board with AstraZeneca, Cancer Prevention and Research Institute of Texas, and Immunovia; research contract with Halozyme Therapeutics; BL reports employment and stock ownership with Bristol-Myers Squibb Company; JM reports employment with Pharmerit International, LP; consulting fees from Celgene (a Bristol-Myers Squibb Company); NJ reports employment with Pharmerit – an OPEN Health Company; consulting with Celgene (a Bristol-Myers Squibb Company); MB reports employment and stock ownership with Pharmerit – an OPEN Health Company and grants from Celgene (a Bristol-Myers Squibb Company).

: Bristol Myers Squibb policy on data sharing may be found at ExternalRef removed.